Page 145 - 《中国药房》2026年5期

Hodgkin lymphomas[J]. Int J Mol Sci，2020，21（6）：2081. Front Pharmacol，2022，13：821344.
[ 6 ] ZHANG J，GU Y，CHEN B A. Drug-resistance mecha‐ [19] ZHU F，WANG K B，RUI L X. STAT3 activation and on‐
nism and new targeted drugs and treatments of relapse and cogenesis in lymphoma[J]. Cancers，2019，12（1）：19.
refractory DLBCL[J]. Cancer Manag Res，2023，15： [20] XIAO S X，FAN C B，MA J L，et al. STAT3 promotes cell
245-255. proliferation by potentiating the CCL4 transcriptional ac‐
[ 7 ] DUELL J，WESTIN J. The future of immunotherapy for tivity in diffuse large B-cell lymphoma[J]. Acta Haematol，
diffuse large B-cell lymphoma[J]. Int J Cancer，2025，156 2022，145（4）：371-383.
（2）：251-261. [21] HU Q，BIAN Q H，RONG D C，et al. JAK/STAT path‐
[ 8 ] NASTOUPIL L J，BARTLETT N L. Navigating the evol- way：extracellular signals，diseases，immunity，and thera‐
ving treatment landscape of diffuse large B-cell lymphoma peutic regimens[J]. Front Bioeng Biotechnol，2023，11：
[J]. J Clin Oncol，2023，41（4）：903-913. 1110765.
[ 9 ] WANG L，LI L R. R-CHOP resistance in diffuse large B- [22] XIN P，XU X Y，DENG C J，et al. The role of JAK/STAT
cell lymphoma：biological and molecular mechanisms[J]. signaling pathway and its inhibitors in diseases[J]. Int Im‐
Chin Med J，2020，134（3）：253-260. munopharmacol，2020，80：106210.

[10] HU X Y，LI J，FU M R，et al. The JAK/STAT signaling [23] GUPTA M，HAN J J，STENSON M，et al. Elevated serum
pathway：from bench to clinic[J]. Signal Transduct Target IL-10 levels in diffuse large B-cell lymphoma：a mecha‐
Ther，2021，6（1）：402. nism of aberrant JAK2 activation[J]. Blood，2012，119
[11] LUO Y M，ALEXANDER M，GADINA M，et al. JAK- （12）：2844-2853.
STAT signaling in human disease：from genetic syn‐ [24] WITZIG T E，PRICE-TROSKA T L，STENSON M J，
dromes to clinical inhibition[J]. J Allergy Clin Immunol， et al. Lack of JAK2 activating non-synonymous mutations
2021，148（4）：911-925. in diffuse large B-cell tumors：JAK2 deregulation still un‐
[12] XUE C，YAO Q F，GU X Y，et al. Evolving cognition of explained[J]. Leuk Lymphoma，2013，54（2）：397-399.
the JAK-STAT signaling pathway：autoimmune disorders [25] BÉGUELIN W，SAWH S，CHAMBWE N，et al. IL10 re‐
and cancer[J]. Signal Transduct Target Ther，2023，8 ceptor is a novel therapeutic target in DLBCLs[J]. Leuke‐
（1）：204. mia，2015，29（8）：1684-1694.
[13] FU X Y，KESSLER D S，VEALS S A，et al. ISGF3，the [26] PARK Y H，SOHN S K，KIM J G，et al. Interaction be‐
transcriptional activator induced by interferon alpha，con‐ tween BCL2 and interleukin-10 gene polymorphisms alter
sists of multiple interacting polypeptide chains[J]. Proc outcomes of diffuse large B-cell lymphoma following
Natl Acad Sci USA，1990，87（21）：8555-8559. rituximab plus CHOP chemotherapy[J]. Clin Cancer Res，
[14] WILKS A F. Two putative protein-tyrosine kinases identi‐ 2009，15（6）：2107-2115.
fied by application of the polymerase chain reaction[J]. [27] ZHANG Y，MA L H，DENG L L，et al. Antitumor effect
Proc Natl Acad Sci USA，1989，86（5）：1603-1607. of dihydroartemisinin on diffuse large B-cell lymphoma
[15] SHAWKY A M，ALMALKI F A，ABDALLA A N，et al. A [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi，2022，30（5）：
comprehensive overview of globally approved JAK inhibi‐ 1428-1434.
tors[J]. Pharmaceutics，2022，14（5）：1001. [28] ROSKOSKI R，Jr. Properties of FDA-approved small mo-
[16] ROSKOSKI R. Janus kinase （JAK） inhibitors in the treat‐ lecule protein kinase inhibitors：a 2024 update[J]. Pharma‐
ment of neoplastic and inflammatory disorders[J]. Pharma‐ col Res，2024，200：107059.
col Res，2022，183：106362. [29] RAYCHAUDHURI S P，RAYCHAUDHURI S K. JAK in‐
[17] VERHOEVEN Y，TILBORGHS S，JACOBS J，et al. The hibitor：introduction[J]. Indian J Dermatol Venereol Lep‐
potential and controversy of targeting STAT family mem‐ rol，2023，89：688-690.
bers in cancer[J]. Semin Cancer Biol，2020，60：41-56. [30] BONELLI M，KERSCHBAUMER A，KASTRATI K，
[18] RAH B，RATHER R A，BHAT G R，et al. JAK/STAT sig‐ et al. Selectivity，efficacy and safety of JAKinibs：new evi‐
naling：molecular targets，therapeutic opportunities，and dence for a still evolving story[J]. Ann Rheum Dis，2024，
limitations of targeted inhibitions in solid malignancies[J]. 83（2）：139-160.

中国药房 2026年第37卷第5期 China Pharmacy 2026 Vol. 37 No. 5 · 687 ·